How have IMTXW shares performed in 2024?

Immatics' stock was trading at $2.92 at the beginning of the year. Since then, IMTXW shares have decreased by 27.4% and is now trading at $2.12. View the best growth stocks for 2024 here .

Are investors shorting Immatics?

Immatics saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 1,400 shares, a decrease of 12.5% from the March 15th total of 1,600 shares. Based on an average trading volume of 4,000 shares, the days-to-cover ratio is currently 0.4 days. View Immatics' Short Interest .

How do I buy shares of Immatics?

Shares of IMTXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IMTXW

Immatics (IMTXW) Stock Price, News & Analysis

→ “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad)

Free IMTXW Stock Alerts

$2.12

-0.25 (-10.55%)

(As of 04/25/2024 ET)

Compare

Today's Range: $2.01
▼
$2.25
50-Day Range: $2.12
▼
$4.14
52-Week Range: $1.49
▼
$4.14

Volume: 4,200 shs
Average Volume: 4,093 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Ownership SEC Filings Short Interest Social Media

Get Immatics alerts:

Ad Stansberry Research

“Retirement Secret” Showed 995% Gain Last Time We Shared It

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

About Immatics Stock (NASDAQ:IMTXW)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

IMTXW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMTXW Stock News Headlines

April 16, 2024 | americanbankingnews.com

Immatics (NASDAQ:IMTXW) Sees Significant Decrease in Short Interest

November 30, 2023 | finance.yahoo.com

Levicept Appoints Eliot Forster as CEO

April 26, 2024 | Stansberry Research (Ad)

“Retirement Secret” Showed 995% Gain Last Time We Shared It

November 2, 2023 | finance.yahoo.com

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

October 31, 2023 | morningstar.com

Adaptive Biotechnologies Corp ADPT

September 23, 2023 | finance.yahoo.com

Immatics N.V. (NASDAQ:IMTX) is definitely on the radar of institutional investors who own 47% of the company

See More Headlines

Receive IMTXW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:IMTXW
CUSIP: N/A
CIK: 1809196
Web: immatics.com
Phone: 4970715397700
Fax: N/A
Employees: 432
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $54.00 million
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Harpreet Singh Ph.D. (Age 49)
CEO, MD, Member of Management Board & Executive Director
Comp: $883.18k
Dr. Toni Weinschenk Ph.D. (Age 50)
Co-Founder & Chief Innovation Officer
Mr. Arnd Christ MBA (Age 58)
Chief Financial Officer
Mr. Steffen Walter Ph.D. (Age 47)
Chief Operations Officer
Mr. Edward A. Sturchio J.D. (Age 48)
General Counsel & Secretary
Dr. Carsten Reinhardt M.D. (Age 57)
Ph.D., Chief Development Officer
Mr. Cedrik M. Britten M.D. (Age 48)
Chief Medical Officer
Mr. Jordan Silverstein (Age 44)
Head of Strategy
Dr. Hans-Georg Rammensee Ph.D.
Co-Founder & Member of the Scientific Advisory Board
Mr. Ephraim Hofsäß M.Sc.
Vice President of SEC Reporting & Accounting

Key Competitors

View All Competitors

IMTXW Stock Analysis - Frequently Asked Questions

How have IMTXW shares performed in 2024?: Immatics' stock was trading at $2.92 at the beginning of the year. Since then, IMTXW shares have decreased by 27.4% and is now trading at $2.12.
View the best growth stocks for 2024 here.
Are investors shorting Immatics?: Immatics saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 1,400 shares, a decrease of 12.5% from the March 15th total of 1,600 shares. Based on an average trading volume of 4,000 shares, the days-to-cover ratio is currently 0.4 days.
View Immatics' Short Interest.
How do I buy shares of Immatics?: Shares of IMTXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMTXW) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial